Enterprise Value
373.3M
Cash
167.4M
Avg Qtr Burn
-20.05M
Short % of Float
10.48%
Insider Ownership
6.84%
Institutional Own.
82.83%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
OP-1250 (palazestrant) (CER antagonist) Details Metastatic breast cancer | Phase 3 Data readout | |
OP-1250 (palazestrant) +palbociclib Details Metastatic breast cancer, Breast cancer | Phase 1/2 Data readout | |
OP-1250 (palazestrant) +ribociclib or alpelisib Details Breast cancer, Metastatic breast cancer | Phase 1b Data readout |